Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Neurorehabilitation Topics in Patients with Multiple Sclerosis: From Outcome Measurements to Rehabilitation Interventions.
A Combination Trial of Copaxone plus Estriol in Relapsing Remitting Multiple Sclerosis
Sphingosine-1-Phosphate (S1P) Impacts Presynaptic Functions by Regulating Synapsin I Localization in the Presynaptic Compartment.
Cervical cord and ventricle affection in neuromyelitis optica.
Treatment Burden and Chronic Illness: Who is at Most Risk?
Induction of a Unique Isoform of the NCOA7 Oxidation Resistance Gene by Interferon β-1b.
The "poison chair" treatment for multiple sclerosis.
Prevalence of people who could benefit from augmentative and alternative communication (AAC) in the UK: determining the need.
A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.
Drugs@FDA
Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
The use of cytokine signature patterns: separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients.
Central nervous system neuroinflammatory disorders in Asian/Pacific regions.
Measuring participation as defined by the World Health Organization in the International Classification of Functioning, Disability and Health. Psychometric properties of the Ghent Participation Scale.
Recent insights into the mechanism of action of glatiramer acetate.
Rare onset symptoms in multiple sclerosis.
CXCR7 Is Involved in Human Oligodendroglial Precursor Cell Maturation.
[The overall assessment of the quality of the physical health of patients with multiple sclerosis after the application of physical therapy. Part 1].
Fumaric acid esters prevent the NLRP3 inflammasome-mediated and ATP-triggered pyroptosis of differentiated THP-1 cells.
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.
Timing of birth and risk of multiple sclerosis: population based study.
Glial cells as drug targets: What does it take?
Multiple sclerosis: Could Helicobacter pylori provide protection against multiple sclerosis?
Immunopathology: autoimmune glial diseases and differentiation from multiple sclerosis.

Pages